Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Isis Signs Two Antisense Pacts
by Rick Mullin
December 17, 2012
| A version of this story appeared in
Volume 90, Issue 51
Isis Pharmaceuticals has formed partnerships with AstraZeneca to discover and develop antisense drugs against five cancer targets and with Biogen Idec for antisense drugs directed at three neurological or neuromuscular disease targets. In exchange for $31 million, Isis will give AstraZeneca an exclusive license to ISIS-STAT3Rx, a compound under development to inhibit STAT3, a protein that drives cancer growth. Isis will receive $30 million from Biogen, with which it is already working on antisense drugs to treat spinal muscular atrophy and myotonic dystrophy. Antisense drugs target the destruction of RNA involved in disease processes.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X